Literature DB >> 17409446

2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.

Andrean L Simons1, Iman M Ahmad, David M Mattson, Kenneth J Dornfeld, Douglas R Spitz.   

Abstract

Glucose deprivation has been hypothesized to cause cytotoxicity by inducing metabolic oxidative stress in human cancer cells. The current work tests the hypothesis that 2-deoxy-d-glucose (2DG) combined with cisplatin [cis-diamminedichloroplatinum(II)] can enhance cytotoxicity in human head and neck cancer cells (FaDu) by mechanisms involving oxidative stress. Exposure of FaDu cells to the combination of 2DG and cisplatin resulted in a significant decrease in cell survival when compared with 2DG or cisplatin alone. Treatment with 2DG and cisplatin also caused perturbations in parameters indicative of oxidative stress, including decreased intracellular total glutathione and increased percentage of glutathione disulfide. Simultaneous treatment with the thiol antioxidant N-acetylcysteine (NAC) inhibited parameters indicative of oxidative stress, as well as protected FaDu cells from the cytotoxic effects of cisplatin alone and the combination of 2DG and cisplatin. In addition, polyethylene glycol-conjugated antioxidant enzymes (PEG-superoxide dismutase and PEG-catalase) also protected FaDu cells from 2DG toxicity. An inhibitor of glutathione synthesis, l-buthionine-[S,R]-sulfoximine (BSO), sensitized FaDu cells to the cytotoxic effects of 2DG and cisplatin, and these effects were inhibited by NAC. Furthermore, the combination of 2DG, cisplatin, and BSO significantly increased the percentage of glutathione disulfide, which was also inhibited by NAC. These results support the hypothesis that exposure of human head and neck cancer cells to 2DG combined with cisplatin enhances cytotoxicity via metabolic oxidative stress. These findings provide a strong biochemical rationale for evaluating inhibitors of glucose and hydroperoxide metabolism in combination with cisplatin for the treatment of head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409446      PMCID: PMC3852417          DOI: 10.1158/0008-5472.CAN-06-3717

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Enzymology of cancer cells (second of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

Review 2.  Enzymology of cancer cells (first of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

3.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

Authors:  T C Hamilton; M A Winker; K G Louie; G Batist; B C Behrens; T Tsuruo; K R Grotzinger; W M McKoy; R C Young; R F Ozols
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

4.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

Authors:  O W Griffith
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

5.  2-Deoxyglucose as a substrate for glutathione regeneration in human and ruminant red blood cells.

Authors:  M Suzuki; J D O'Dea; T Suzuki; N S Agar
Journal:  Comp Biochem Physiol B       Date:  1983

6.  2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo.

Authors:  Gregory Maschek; Niramol Savaraj; Waldemar Priebe; Paul Braunschweiger; Kara Hamilton; George F Tidmarsh; Linda R De Young; Theodore J Lampidis
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

Review 7.  Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Authors:  Zahid H Siddik
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 8.  The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors:  Danyelle M Townsend; Kenneth D Tew
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.

Authors:  DeeDee K Smart; Karen L Ortiz; David Mattson; C Matthew Bradbury; Kheem S Bisht; Leah K Sieck; Martin W Brechbiel; David Gius
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

10.  Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis.

Authors:  B A Arrick; O W Griffith; A Cerami
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  98 in total

1.  A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.

Authors:  Murugesan K Gounder; Hongxia Lin; Mark Stein; Susan Goodin; Joseph R Bertino; Ah-Ng Tony Kong; Robert S DiPaola
Journal:  Biomed Chromatogr       Date:  2011-09-19       Impact factor: 1.902

2.  Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.

Authors:  Lei Gong; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Jirun Peng; Xisheng Leng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

3.  Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model.

Authors:  Vlad C Sandulache; Yunyun Chen; Heath D Skinner; Tongtong Lu; Lei Feng; Laurence E Court; Jeffrey N Myers; Raymond E Meyn; Clifton D Fuller; James A Bankson; Stephen Y Lai
Journal:  Mol Cancer Ther       Date:  2015-09-16       Impact factor: 6.261

4.  Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer.

Authors:  Xianhan Jiang; Xun Li; Hai Huang; Funeng Jiang; Zhuoyuan Lin; Huichan He; Yanru Chen; Fei Yue; Jing Zou; Yongzhong He; Pan You; Wenwei Wang; Weiqing Yang; Haibo Zhao; Yiming Lai; Fen Wang; Weide Zhong; Leyuan Liu
Journal:  Cancer       Date:  2014-01-03       Impact factor: 6.860

5.  Regulation of glycolysis in head and neck squamous cell carcinoma.

Authors:  Dhruv Kumar
Journal:  Postdoc J       Date:  2017-01

6.  p53 Protects lung cancer cells against metabolic stress.

Authors:  Chompunoot Sinthupibulyakit; Wanida Ittarat; William H St Clair; Daret K St Clair
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

Review 7.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

8.  Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.

Authors:  Tanja Hadzic; Nükhet Aykin-Burns; Yueming Zhu; Mitchell C Coleman; Katie Leick; Geraldine M Jacobson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

Review 9.  Targeting mitochondria in cancer: current concepts and immunotherapy approaches.

Authors:  Sergey Pustylnikov; Francesca Costabile; Silvia Beghi; Andrea Facciabene
Journal:  Transl Res       Date:  2018-07-31       Impact factor: 7.012

10.  Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.

Authors:  David M Mattson; Iman M Ahmad; Disha Dayal; Arlene D Parsons; Nukhet Aykin-Burns; Ling Li; Kevin P Orcutt; Douglas R Spitz; Kenneth J Dornfeld; Andrean L Simons
Journal:  Free Radic Biol Med       Date:  2008-10-18       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.